Warning Issued to Texas Pharmacists About Diverted HIV Medicines Sold on Online Platforms

ADAP Advocacy and the Partnership for Safe Medicines (PSM) have issued a joint warning to pharmacists regarding the purchase of discounted HIV medicines from online pharmacy-to-pharmacy (P2P) marketplaces. According to the statement released June 30, 2026, these products meet the definition of suspect product under U.S. Food and Drug Administration (FDA) guidelines and the Drug Supply Chain Security Act. Pharmacies are urged not to buy from these platforms, and any HIV medicines obtained through such channels should be quarantined and verified before dispensing, as patients living with HIV/AIDS are potentially being put at risk.

PSM's Executive Director, Shabbir Imber Safdar, explained that deeply discounted HIV products bought from unknown sellers without a pedigree qualify as suspect even before receipt, as the listings meet several FDA risk criteria for illegitimacy, including deep discounts, established fraud patterns in the HIV drug supply chain over the past six years, unknown sellers, and incomplete transaction histories. Once received, damaged packaging often confirms the need for quarantine and investigation.

While online P2P marketplaces help pharmacies manage inventory, they pose risks of suspicious sales. Dispensers must quarantine and investigate suspect products and report illegitimate products to the FDA and partners within 24 hours. Brandon M. Macsata, CEO of ADAP Advocacy, also warned that independent pharmacies have been known to trade stock in less formal settings such as WhatsApp or Telegram, which are even more vulnerable and never advisable.

The full warning is available online at https://www.safemedicines.org/diverted-hiv-meds-on-p2p-platforms. This warning is critical for Texas pharmacists and the broader healthcare industry, as it highlights the dangers of purchasing discounted HIV medications from unverified sources. The implications are significant: patients could receive adulterated or ineffective medicines, leading to treatment failure, drug resistance, and increased transmission risks. Pharmacies that fail to comply with the Drug Supply Chain Security Act may face regulatory action and liability. By heeding this warning, pharmacists can protect patient safety and maintain the integrity of the pharmaceutical supply chain in Texas.